Flatiron Health

New York, NY, USA All United States companies → — Founded 2012

EMR / EHR Platform Healthcare Analytics / BI Specialty-Focused AI

Hematology Oncology

Clinical Decision Support & Reference Oncology AI

Acquired (by Roche in 2018) — $314M (prior to acquisition)

Website Claim this company

Products

Flatiron Health OncologyCloud

Flatiron Health

Clinical Decision Support & Reference

Flatiron Health is a healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer.

Not publicly available for the full oncologycloud suite; api pricing details are available.

See all 1 product →

About Flatiron Health

Flatiron Health is a leading healthtech company dedicated to transforming cancer care and accelerating research through advanced clinical and data science. For physicians, Flatiron provides an oncology-specific Electronic Health Record (EHR) system, OncoEMR®, designed to optimize clinical workflows, offer evidence-based treatment options, and integrate seamlessly with various tools for molecular profiling and clinical decision support via Flatiron Assist™. The platform also includes robust analytics capabilities through Flatiron Insight™ to help practices monitor their operational and financial health.

The company’s core mission involves translating real-life patient experiences into high-quality real-world evidence (RWE). This evidence is crucial for improving treatment strategies, informing healthcare policy, and advancing clinical trials. Flatiron partners with over 280 community cancer centers and academic medical centers, as well as pharmaceutical companies, researchers, and regulatory bodies, to build a more connected and data-driven oncology ecosystem.

Flatiron Health’s offerings extend to supporting clinical research by providing solutions for trial recruitment, site enablement, and EHR-to-EDC (Electronic Health Record to Electronic Data Capture) connectors. These tools simplify data management for clinical studies, reduce manual data entry, and enhance the efficiency of clinical trials, ultimately aiming to close the gap between patient care and research to improve outcomes for every person with cancer.

Focus Areas

Oncology Real-World Evidence AI/Machine Learning Electronic Health Records (EHR) for Oncology Clinical Research Data Curation and Analytics Personalized Medicine Health Equity

Business Intelligence

Key Investors	Roche, Google Ventures, First Round Capital, LabCorp, Baillie Gifford, Casdin Capital, Allen & Company, Stripes
Partnerships	Paradigm Health (acquired Clinical Research business and strategic partnership), Massive Bio, NRG Oncology, FDA (renewed research collaboration), Abbott, Natera, Adaptive Biotechnologies
Acquisitions	Acquired by Roche (2018), acquired Altos Solutions, Clinical Research business acquired by Paradigm Health (2025)
Technology	Cloud-based oncology software platform, OncoEMR® (oncology-specific EHR), OncoAnalytics®, Flatiron Clinical Pipe™ (EHR-to-EDC connector), AI and machine learning capabilities for data curation and patient identification, Large Language Models (LLMs)
FDA Clearances	Flatiron Health's real-world data (RWD) has supported several FDA approvals and new dosing regimens for oncology treatments (e.g., ERBITUX®, Ibrance, Lumakras). They also maintain a multi-year research collaboration with the FDA to advance the use of RWD and explore its strengths and limitations for regulatory purposes. cleared products (estimated)

What Physicians Need to Know

Oncology-Specific EHR

Flatiron Health's flagship product, OncoEMRu00ae, is a cloud-based Electronic Medical Record system meticulously designed for community oncology practices. It supports efficient, personalized, and evidence-based cancer care across the patient journey, offering intuitive workflows and customizable templates.

Real-World Evidence (RWE) & Data Curation

Flatiron specializes in generating high-quality Real-World Evidence by sourcing, capturing, normalizing, and curating vast amounts of structured and unstructured oncology data from EHRs, laboratories, and other sources. A dedicated team of over 500 nurses, certified tumor registrars, and clinical research associates meticulously curates this data, ensuring its accuracy and relevance for research. Their Flatiron Horizon platform integrates labeled oncology data, proprietary curation methods, and disease-specific ML models to deliver industry-leading RWE solutions.

AI/Machine Learning for Advanced Insights

Leveraging AI and machine learning, including large language models (LLMs), Flatiron extracts real-world progression data at an unprecedented scale. They have developed the Validation of Accuracy for LLM/ML-Extracted Information and Data (VALID) Framework to ensure the highest quality of AI-extracted data, enabling predictive modeling and deeper insights into patient outcomes and treatment effectiveness.

Clinical Research Enablement

Flatiron's platform facilitates more efficient clinical research by enabling data-backed identification of eligible trial patients directly within the EHR. It also supports the digital transfer of relevant study data seamlessly between the EHR and Electronic Data Capture (EDC) systems, and offers services for protocol optimization, patient recruitment, and site selection.

Personalized Medicine Support

Through integrations with leading precision oncology test providers (e.g., Abbott, Guardant Health, Natera), OncoEMRu00ae allows clinicians to digitally order comprehensive genomic profiling and other advanced tests, receive status updates, and view results directly within their existing clinical workflow. This streamlines access to critical information for informed, personalized treatment decisions.

Health Equity Initiatives

Flatiron is actively expanding its focus on health equity and disparities research. By generating high-quality real-world evidence, they aim to help researchers address disparities in cancer care and provide clinicians with the insights needed to make smarter, faster decisions across diverse patient populations.

Robust Technology Stack

Flatiron's infrastructure is cloud-native, primarily leveraging Amazon Web Services (AWS) for scalable and secure operations, including Amazon EC2, S3 (with HIPAA-eligible encryption for PHI), VPC, VPN, and IAM. They also utilize Fast Healthcare Interoperability Resources (FHIRu00ae) APIs for secure and standardized data exchange with third-party applications.

Physician Tip

For physicians, Flatiron Health stands out by providing an oncology-specific EHR (OncoEMRu00ae) that streamlines daily workflows, reduces administrative burden, and supports evidence-based and personalized care. The seamless integration of precision oncology test ordering and results directly within the EMR saves valuable time and ensures timely access to actionable insights for treatment decisions. The platform's ability to surface real-world evidence and up-to-date treatment guidelines empowers oncologists to make smarter, faster decisions, ultimately improving patient outcomes and the overall care experience. Flatiron's commitment to data quality and clinician-engineer collaboration ensures that their tools are clinically relevant and user-friendly.

Flatiron Health's OncoEMRu00ae platform is designed for extensive interoperability, utilizing FHIRu00ae APIs to integrate with a broad ecosystem of third-party applications and diagnostic providers. Key integrations include precision oncology testing companies like Abbott, Guardant Health, Natera, Adaptive Biotechnologies, and Tempus, enabling seamless electronic ordering and results delivery directly within the clinical workflow.

At a glance

Founded 2012

HQ New York, NY, USA · United States

Team size Over 2,500 employees

CEO Nathan Hubbard

Funding Acquired (by Roche in 2018) — $314M (prior to acquisition)

FDA clearances Flatiron Health's real-world data (RWD) has supported several FDA approvals and new dosing regimens for oncology treatments (e.g., ERBITUX®, Ibrance, Lumakras). They also maintain a multi-year research collaboration with the FDA to advance the use of RWD and explore its strengths and limitations for regulatory purposes. (estimated)

Products 1

Visit site

Products by Flatiron Health

1 product in the directory

Flatiron Health OncologyCloud

Flatiron Health

Clinical Decision Support & Reference

Flatiron Health is a healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer.

Not publicly available for the full oncologycloud suite; api pricing details are available.

What the Web Says

Flatiron Health is a health technology company focused on improving cancer care through data and real-world evidence. The company generally receives positive reviews for its mission-driven culture, flexible work environment, and supportive colleagues. However, some employees have raised concerns about management communication, transparency, and opportunities for advancement, as well as product quality and reporting functionalities.

Overall: Mixed

Strengths

Strong mission to fight cancer and improve patient care.
Flexible work hours and remote-friendly options, particularly for data abstractor roles.
Positive work-life balance.
Supportive, kind, and collaborative colleagues.
Good benefits and compensation package, including stock offerings with Roche.
Opportunities for professional development and learning.

Limitations

Inconsistent management communication and transparency.
Limited opportunities for job security and advancement for some roles.
Product quality concerns and poor reporting functionality in some software (e.g., OncoEMR).
Work can be repetitive or boring at times.
Some employees feel undervalued or stretched thin.
Potential for organizational turmoil.

Based on reviews from: Indeed.com, Comparably, Built In, Reddit, Capterra, Quora, Handshake

Last updated: 2026-07-24

Videos

News, demos, and interviews about Flatiron Health.

Loading videos...

Videos load interactively. If none appear, search YouTube for Flatiron Health →

View all on YouTube

Press & Coverage

Flatiron Health

Flatiron Health launches Flatiron Telescope, a new AI platform delivering oncology insights in minutes

Flatiron Health has launched Flatiron Telescope, a new AI-powered platform designed to accelerate oncology research by providing faster patient insights and data-driven decisions. This platform allows life sciences teams and researchers to find the right patients faster, assess study feasibility in real time, and generate oncology insights on demand.

2026-07

Flatiron Health

Flatiron Health Expands Global Oncology Network Through First Partnership in Scotland

Flatiron Health announced a new partnership with NHS Greater Glasgow and Clyde (NHSGGC), marking its first collaboration in Scotland and expanding its international oncology network across the UK, Germany, and Japan. This partnership aims to transform routine cancer care information into high-quality, research-ready real-world data to deepen Flatiron's multinational evidence base.

2026-07

Flatiron Health

Flatiron Health brings 49+ research acceptances and next-generation capabilities to ASCO 2026

Flatiron Health announced its significant presence at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting, featuring over 49 research acceptances, including 14 Flatiron-authored poster presentations and online publications. The company showcased its high-quality real-world data and innovative research capabilities, including demonstrations of its new Flatiron Telescope AI platform.

2026-05

Flatiron Health

Flatiron Health publishes first peer-reviewed validation framework for AI-extracted real-world oncology data in Journal of Clinical Oncology

Flatiron Health announced the publication of its Validation of Accuracy for LLM/ML-Extracted Information and Data (VALID) Framework in the Journal of Clinical Oncology Clinical Cancer Informatics. This framework is the first comprehensive, peer-reviewed approach to evaluating the quality and reliability of real-world data extracted by large language models and machine learning in oncology research.

2026-04

Flatiron Health

Flatiron Health Raises $175 Million Series C Round to Further Bolster its OncologyCloud Software Platform for Providers and Accelerate Personalized Medicine

Flatiron Health secured $175 million in Series C funding led by Roche, with participation from Allen & Company, Baillie Gifford, and Casdin Capital. The funding will be used to further invest in its cloud-based OncologyCloud software platform, including OncoAnalytics and OncoEMR, to enhance patient care and accelerate personalized medicine.

2016-01

Flatiron Health

Flatiron Health enters new five-year research collaboration with FDA on real-world data

Flatiron Health renewed its five-year research collaboration with the Oncology Center of Excellence (OCE) of the United States Food and Drug Administration (FDA). The partnership aims to advance the use of real-world data (RWD) and explore its potential for regulatory purposes by jointly developing research projects on cancer patient care, treatment, and outcomes.

2023-09

Flatiron Health

Quest Diagnostics Now the Largest Clinical Reference Lab to Extend Oncology Test Access Through OncoEMR MPI

Quest Diagnostics has become the largest clinical reference lab to extend oncology test access through Flatiron Health's OncoEMR MPI. This collaboration aims to improve access to oncology testing and streamline data for cancer care.

2026-07

Flatiron Health

New research confirms data quality as the defining priority across the real-world evidence landscape

New research, including insights from two independent surveys, confirms that data quality and cohort scale are paramount in the real-world evidence landscape, especially with the industry's shift towards predictive and AI-driven applications in oncology.

2026-07

Frequently Asked Questions

How does Flatiron Health leverage Real-World Evidence (RWE) to improve oncology treatment decisions and support personalized medicine?

Flatiron Health generates high-quality RWE by curating longitudinal, patient-level data from a vast network of oncology EHRs, encompassing over 5 million patient records. This RWE helps researchers address disparities, provides clinicians with insights for smarter decisions, and supports the development of personalized medicine by understanding treatment effectiveness and patient outcomes across diverse tumor types.

What are the core capabilities of Flatiron's OncoEMRu00ae for oncology practices, and how does it integrate with AI/Machine Learning for data-driven insights?

Flatiron's OncoEMRu00ae is a cloud-based, ONC-certified EHR specifically designed for oncology, offering features like customizable templates, integrated clinical content, and support for molecular profiling and clinical trials. It leverages machine learning and AI capabilities to optimize cancer treatment plans, match patients with appropriate clinical trials, and streamline workflows by reducing manual data entry through integrations with ambient AI solutions.

How does Flatiron Health support and accelerate clinical research and trials for oncology practices?

Flatiron Health accelerates clinical research by using its real-world data to design smarter trials, optimize protocols, and identify eligible patients faster through technology and centralized services. Products like Flatiron Clinical Pipeu2122 connect EHRs to Electronic Data Capture (EDC) systems, enabling seamless data transfer, reducing site burden, and accelerating study timelines.

What is Flatiron Health's process for data curation and analytics, ensuring the quality and reliability of real-world data for research and health equity initiatives?

Flatiron Health employs a hybrid data curation methodology combining manual abstraction by clinical experts with automated extraction using machine learning, natural language processing (NLP), and large language models (LLMs) to process both structured and unstructured EHR data. This rigorous process, validated by quality frameworks, ensures high-quality, reliable real-world data that can be used to study health disparities and promote health equity.

What are Flatiron Health's primary product offerings for oncology providers, and what level of support and compliance can practices expect?

Flatiron Health's primary offerings include OncoEMRu00ae for comprehensive oncology EHR management, Flatiron Assistu2122 for evidence-based decision support and prior authorization, and OncoAiru2122 for mobile access to patient information. These products are ONC-certified, and the company is committed to providing best-in-class technology with robust support and compliance with regulatory standards like HIPAA.

How does Flatiron Health ensure data privacy, security, and regulatory compliance (e.g., HIPAA) when utilizing patient data for research and analytics?

Flatiron Health de-identifies patient data in accordance with HIPAA privacy rules before it is used for research purposes, ensuring that personally identifiable information is never shared with third parties. They maintain physical, technical, and administrative controls to protect privacy and, in rare cases where de-identified data isn't sufficient for internal research, they adhere to HIPAA standards by using only the minimum necessary data with direct identifiers removed.

What is the typical pricing structure for Flatiron Health's solutions, and how does it demonstrate value and return on investment for healthcare administrators?

Flatiron Health primarily generates revenue through subscription fees for its oncology-specific software and data analytics platforms, with pricing often tiered based on the size and scope of the cancer center's operations. Their solutions aim to demonstrate value by streamlining workflows, providing actionable insights that lead to more informed treatment decisions, and supporting participation in value-based care models, which can improve operational efficiency and financial viability.

What is Flatiron Health's long-term vision for partnerships and company stability, particularly in the context of its relationship with Roche?

Flatiron Health, an independent affiliate of the Roche Group since its acquisition in 2018, maintains its autonomy and continues to expand its network of partnerships with life science companies, academic centers, and technology providers like Veeva and DeepScribe. This relationship with Roche and ongoing collaborations reinforce Flatiron's stability and commitment to accelerating cancer research and improving patient care across the industry.